Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.
about
Safety and efficacy of enzyme replacement therapy in the nephropathy of Fabry diseaseCardiomyopathy and response to enzyme replacement therapy in a male mouse model for Fabry diseaseThe vascular effects of infection in Pediatric Stroke (VIPS) Study.Prevalence of chronic kidney disease in fabry disease patients: Multicenter cross sectional study in Argentina.Functional studies of new GLA gene mutations leading to conformational Fabry disease.Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies.Inflammatory biomarkers of vascular risk as correlates of leukoariosis.Cellular and tissue distribution of intravenously administered agalsidase alfa.Novel therapeutic targets for the treatment of Fabry disease.Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidaseGlobotriaosylceramide induces oxidative stress and up-regulates cell adhesion molecule expression in Fabry disease endothelial cells.Biomarkers and Imaging Findings of Anderson-Fabry Disease-What We Know Now.Genetic variants influencing elevated myeloperoxidase levels increase risk of stroke.Apoptotic abnormalities in differential gene expression in peripheral blood mononuclear cells from children with Fabry disease.Fabry diseaseSerum Biomarkers of Endothelial Dysfunction in Fabry Associated Cardiomyopathy
P2860
Q24650910-327AFAAB-2BA4-4C78-83D1-E4927BBD9AD8Q28730130-147937D0-BAAC-4A53-B79F-02D43F57B7D2Q30425204-74FADBD7-B87A-45D5-ABC0-62CF5C75080DQ33726258-17C790C4-3452-4AFA-A9D2-C9F3057C258AQ34665552-18779FE7-823A-40B9-9494-9256BFD143F0Q35028532-000485E1-7931-4F39-A0BB-550DF902EB93Q35045118-30B9FFB1-52B1-4C07-A94B-63369DE9BDDDQ35728693-B44FC92C-1B66-483E-B0B8-A040AA9D1EF1Q36822452-37834A0C-8849-4B42-B4D4-F98922FE81D2Q36985114-4F1EEF98-A386-4694-97FF-70E6C332A200Q36995447-9A7BF0C6-7A34-47AC-BA27-46C5FA763885Q41297721-90EEE583-D33B-4EDE-8A21-677F67A83F5DQ45069028-BF6477D7-05EA-4AE7-9B52-B08BCB3B512FQ54531507-32BCE7C8-33B5-475D-A5C1-6AD2AFB99F51Q56905945-64A96D13-32CF-4D77-9A46-1FF7AF3D0104Q58777263-3163D41E-D8A7-4900-9B2B-24A9A0386D41
P2860
Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Myeloperoxidase predicts risk ...... gous males with Fabry disease.
@ast
Myeloperoxidase predicts risk ...... gous males with Fabry disease.
@en
type
label
Myeloperoxidase predicts risk ...... gous males with Fabry disease.
@ast
Myeloperoxidase predicts risk ...... gous males with Fabry disease.
@en
prefLabel
Myeloperoxidase predicts risk ...... gous males with Fabry disease.
@ast
Myeloperoxidase predicts risk ...... gous males with Fabry disease.
@en
P2093
P2860
P1433
P1476
Myeloperoxidase predicts risk ...... ygous males with Fabry disease
@en
P2093
G C Zirzow
R Schiffmann
P2860
P304
P356
10.1212/01.WNL.0000247278.88077.09
P407
P577
2006-12-01T00:00:00Z